-
Clinical trials of pharmacotherapy to prevent progression of cognitive decline in those with mild cognitive impairment (MCI) have been disappointing; neither cholinesterase inhibitors (donepezil, rivastigmine, galantamine), vitamin E, nor COX-2 inhibitors has demonstrated any clinically meaningful benefit in placebo-controlled MCI trials.
-
The ECG shown above was obtained from a patient who was seen in the office with atypical chest pain. Is there cause for concern?
-
Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
In knee OA, arthroscopic surgery confers no benefit.
-
Whereas racial concordance is the primary predictor of perceived ethnic similarity, patients do value higher communication skills, which may actually result in better outcomes.
-
The FDA has approved the first drug for the treatment of Huntington's disease.
-
-
Success has raised the bar. No sooner did infection preventionists (IPs) begin demonstrating that it was actually possible to drive certain infection rates down to a vanishing point when federal payers essentially said, "Good, keep them at zero because we are not paying for them."
-
In a finding that will increase national calls for oversight of ambulatory care settings, seven patients reportedly acquired hepatitis C infection while undergoing stress tests at a cardiology practice in Larinburgh, NC.
-
Proposed state laws in Nevada in the wake of a highly-publicized hepatitis C outbreak in Las Vegas include proposals to hire infection preventionists (IPs) as consultants to oversee practice in freestanding clinics.
